In vitro and in vivo activity of moxifloxacin against community respiratory tract pathogens

被引:20
作者
Blondeau, JM
Felmingham, D
机构
[1] GR Micro Ltd, London NW1 3ER, England
[2] Saskatoon & Dist Hlth, Div Clin Microbiol, Saskatoon, SK, Canada
[3] Univ Saskatchewan, Saskatoon, SK S7N 0W0, Canada
关键词
D O I
10.2165/00044011-199918010-00007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The high prevalence of respiratory tract infections (RTIs) and the increasing resistance of causative pathogens to currently available antibiotics necessitates the development of new, more powerful antimicrobial agents. Such agents must possess a broad spectrum of antibacterial activity so as to be useful for both the empirical and specific therapy of RTIs. Moxifloxacin is one such antimicrobial agent. The drug is a new 8-methoxyquinolone that has been shown to have a wide range of activity against Gram-positive and -negative bacteria as well as against anaerobes and atypical pathogens that can cause RTIs. Moxifloxacin is also effective against both beta-lactam- and macrolide-resistant organisms and very rarely itself induces resistance under experimental conditions. This review summarises the in vitro evidence far the range of antibacterial activities of moxifloxacin, in terms of minimum inhibitory concentrations (MIC90), time-kill kinetics and post-antibiotic effects. These in vitro findings have been confirmed by animal studies. In conclusion, moxifloxacin has an effective, appropriate spectrum of antimicrobial activity and other properties that provide a foundation for its use in the therapy of RTIs.
引用
收藏
页码:57 / 78
页数:22
相关论文
共 134 条
[1]   Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus [J].
Al-Nawas, B ;
Shah, PM .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (06) :655-658
[2]   In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients [J].
Alcaide, F ;
Carratala, J ;
Linares, J ;
Gudiol, F ;
Martin, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) :2117-2120
[3]   Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes [J].
Aldridge, KE ;
Ashcraft, DS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) :709-711
[4]   Strategies and options for minimizing resistance emergence in pulmonary infections [J].
Amyes, SGB .
CHEST, 1998, 113 (03) :228S-232S
[5]   Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic bronchoscopy [J].
Andrews, JM ;
Honeybourne, D ;
Brenwald, NP ;
Bannerjee, D ;
Iredale, M ;
Cunningham, B ;
Wise, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (06) :797-802
[6]   ANTIMICROBIAL RESISTANCE IN STREPTOCOCCUS-PNEUMONIAE - AN OVERVIEW [J].
APPELBAUM, PC .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (01) :77-83
[7]   Acute exacerbations of chronic bronchitis - An international comparison [J].
Ball, P ;
Make, B .
CHEST, 1998, 113 (03) :199S-204S
[8]  
BALL P, 1998, EXP OPIN INVEST DRUG, V7, P1
[9]  
Bartlett J G, 1997, Semin Respir Infect, V12, P329
[10]   Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin [J].
Bauernfeind, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (05) :639-651